Recent Updates
Recently added Catalysts

PDC-1421

Phase 2

Major Depressive Disorder | Small molecule | Psychiatry |ABVC BioPharma, Inc.|Last Updated: Apr 20, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment114
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02395978A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive DisorderPHASE2 COMPLETED 72Apr 10, 2015Mar 18, 2019Jul 22, 20215 United States, Taiwan
NCT03833206A Phase I/II Study of PDC-1421 for Treating Depression in Cancer PatientsPHASE1 NOT YET_RECRUITING 12Jan 15, 2027Feb 28, 2028Apr 20, 20261 United States
NCT01774045A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in DepressionPHASE1 COMPLETED 30Nov 1, 2012Jul 1, 2013Aug 13, 20201 Taiwan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II.
From Baseline to Week 6

The MADRS is a 10-item checklist of depressive symptoms. Each Item is rated on a scale of 0-6, with anchors at 2-point intervals; higher scores indicating more severity (i.e., ranging from 0 \[no sadness\] to 6 extremely despondent\]). The total MADRS score was calculated by summing the ratings of all items. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity).

Montgomery-Åsberg Depression Rating Scale (MADRS)
5 weeks

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 1, 2, 3, 4, and 5 in patients taking 1 or 2 PDC-1421 capsules. The MADRS is a 10-item checklist including 1) depression \[apparent\]; 2) depression \[reported\]; 3) loss of interest; 4) suicidal ideation; 5) tension; 6) reduced appetite; 7) insomnia; 8) difficulty in activities; 9) concentration; and 10) pessimism. The MADRS is administered by a trained interviewer. Each item is rated on a scale of 0-6, with anchors at 2-point intervals; higher scores indicating more severity (i.e., ranging from 0 \[no sadness\] to 6 \[extremely despondent\]). The total score is used to define treatment response (≥50% reduction from baseline) and partial response (20-49% reduction from baseline). Remission is defined as a score of \< 10. The following are used as an interpretation of scores: 0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression \>34 - severe depression

Number of Dose Limiting Toxicity of Physical Examination
baseline to 72 hours

Physical examination, including skin, head, neck, eyes, ears, nose, throat, heart, lungs, abdomen (liver and spleen), neurological examination, lymph node and extremities, is measured at each visit from screening to follow-up.

Number of Dose Limiting Toxicity of Electrocardiograph
baseline to 72 hours

Electrocardiograph (ECG) is measured at each visit. At visit 2, subjects were measured at 1,2, 4, 8, 12 and 24 hours after drug administration.

Number of Dose Limiting Toxicity of Vital Sign
baseline to 72 hours

Vital sign, including heart rate, blood pressure and body temperature, are measured at each visit and at 1,2,3,4,8,12 and 24 hours after drug administration.

Number of Dose Limiting Toxicity of Laboratory Values
baseline to 72 hours

Laboratory tests are composed of hematology and blood chemistry and measured at each visit. Hematology are composed of RBC, WBC, platelets, hematocrit, hemoglobin, prothrombin time (PT) and partial thromboplastin time (aPTT). Blood chemistry are composed of AST, ALT, LDH, total bilirubin, BUN, serum creatinine, free thyroxine (FT4), TSH, sodium, calcium, potassium, glucose, LDL, HDL, cholesterol and HbA1c.

Number of Dose Limiting Toxicity of Columbia-Suicide Severity Rating Scale (C-SSRS)
baseline to 72 hours

C-SSRS is composed of suicidal ideation, intensity of ideation and suicidal behavior and measured at each visit.

Secondary Endpoints
Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 2, 4 and 7 Part II.
From Baseline to Week 2, 4, 7
Change of Hamilton Depression Rating Scale (HAM-D-17) Total Score From Baseline to Week 2, 4, 6 and 7 for Part II.
From Baseline to Week 2, 4, 6 and 7
Change of Hamilton Anxiety Rating Scale (HAM-A) Total Score From Baseline to Week 2, 4, 6 and 7 for Part II.
From Baseline to Week 2, 4, 6 and 7
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part I: 1 PDC-1421 CapsuleEXPERIMENTAL1 PDC-1421 Capsule TID, p.o. after meal for 28 days
Part I: 2 PDC-1421 CapsuleEXPERIMENTAL2 PDC-1421 Capsule TID, p.o. after meal for 28 days
Part II: 2 PDC-1421 CapsuleEXPERIMENTAL2 PDC-1421 Capsule TID, p.o. after meal for 42 days
Part II: 1 PDC-1421 Capsule plus 1 placeboEXPERIMENTAL1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
Part II: 2 placeboPLACEBO_COMPARATOR2 placebo TID, p.o. after meal for 42 days
1 PDC-1421 CapsuleEXPERIMENTAL1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
2 PDC-1421 CapsulesEXPERIMENTAL2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
PDC-1421EXPERIMENTALDosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
Placebo controlPLACEBO_COMPARATORDosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
Interventions
NameTypeDescription
PDC-1421 CapsuleDRUGPDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
placeboDRUGPlacebo contained corn starch.
PDC-1421DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: 1. Outpatients aged 20-65 years 2. Subjects must be able to understand and willing to sign informed consent 3. Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later aft...

Countries:United StatesTaiwan
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT03833206Phase: PHASE2 → PHASE1
LOWMay 24, 2026NCT03833206studyFirstPostDate: changed